



December 22, 2023

Company name: LinqMed Inc.  
Representative: Yukie Yoshii

## LinqMed Announces Series A and additional Financing

CHIBA, JAPAN – December 22<sup>th</sup>, 2023 –LinqMed Inc. (CEO Yukie Yoshii, Headquarters: Chiba-shi, Chiba, Japan, “LinqMed”), a radiopharmaceutical company focusing on the development of innovative “visible” anti-cancer treatments to patients, announced the closing of a JPY 680 million Series A equity financing. Together with funds raised through J-KISS-type stock acquisition rights, which is contingent on the completion of the Series A financing, the total amount raised is JPY 930 million.

The financing was led by DBJ Capital Co., Ltd., and joined with Iwabuchi Corporation, PeptiDream Inc., Taisho Pharmaceutical Holdings, Mizuho Capital, Osaka Kansai Expo activation investment limited partnership, Green Core, Ltd. and Shiratori Pharmaceutical Co., Ltd..

As announced in a separate release today, LinqMed has been selected by NEDO (New Energy and Industrial Technology Development Organization) to receive support from the Deep-Tech Startup Support Fund/Deep-Tech Startup Support Program. With the goal to establish a platform supporting <sup>64</sup>Cu-based drug discovery and create a new industry, the funds raised through the Series A, together with the award from NEDO will be used to install a cyclotron and build drug formulation facilities necessary for large-scale manufacturing capabilities to produce radiopharmaceuticals using <sup>64</sup>Cu in Japan. (please refer to “LinqMed selected by NEDO to receive award from the Deep-Tech Startup Support Program”).

In addition, as announced in another separate release today, LinqMed and PDRadiopharma Inc., a wholly owned subsidiary of PeptiDream Inc., entered into a strategic partnership to jointly develop and commercialize <sup>64</sup>Cu-ATSM, LinqMed’s first development program for the treatment of malignant brain tumor in Japan (please refer to “LinqMed and PeptiDream Announce Strategic Partnership for Development and Commercialization of Radiopharmaceutical Agent <sup>64</sup>Cu-ATSM in Japan.”) LinqMed plans to conduct a confirmatory clinical trial of <sup>64</sup>Cu-ATSM in Japan to assess its efficacy and safety.

*“We raised a total of 930 million yen in a Series A financing. This time, we welcomed some new investors in addition to our current shareholders. In addition, we are really pleased to inform you that LinqMed. is granted the financial support by Deep-Tech Startup Support Project of NEDO. This Series A financing and NEDO’s funding support are extremely significant achievement of ours to accelerate our R&D and business activities. We will construct a new manufacturing facility equipped with an innovative <sup>64</sup>Cu mass production system to expedite the development of our own pipeline. This <sup>64</sup>Cu technology can further work as a platform to support drug development activities in Japanese and global pharmaceutical industries. We believe that this is a primary but enormous step to provide innovative “visible” anti-cancer treatments to society and save many patients suffering from life-threatening diseases”* said **Yukie Yoshii, CEO of LinqMed.**

*“We are very pleased to be the lead investor for Linqmed, a company with a drug discovery platform using <sup>64</sup>Cu, a radioisotope which is expected to combine both therapeutic and diagnostic capabilities. The Development Bank of Japan (DBJ) has*

been supporting female entrepreneurs since 2012 through the DBJ Women's New Business Plan Competition. LinqMed CEO Yukie Yoshii was awarded the 9<sup>th</sup> DBJ Women's Entrepreneurship Excellence Award in 2022 and following LinqMed's subsequent growth, DBJ Capital, a VC subsidiary of DBJ, invested in the company. One of the DBJ Group's core mission is to "promote Japan's economic growth through support for innovation". Through this investment, the DBJ Group hopes to support LinqMed's efforts to bring breakthrough treatments and diagnostics for refractory cancers from Japan to patients around the world." said **Masahiko Niimi, CEO of DBJ Capital Co., Ltd.**

"We have invested in LinqMed since its inception after meeting CEO Yoshii of Linqmed at a business contest in Chiba Prefecture and we have made additional investment in this Series A round. We believe that LinqMed, with its manufacturing technology for <sup>64</sup>Cu, the only radioisotope capable of both diagnosis and treatment, will make a significant contribution to unmet medical needs through the development of novel radiopharmaceuticals in Japan. In addition to investments, we will maximize the product value after launch by leveraging our relationships with medical institutions and pharmaceutical manufacturers and our know-how, which we have cultivated through our main business of pharmaceutical wholesaling, through optimal distribution and the development of a therapeutic environment at medical institutions. We also expect the start-up company from Chiba Prefecture to expand globally and contribute to patients around the world." said **Takuma Iwabuchi, CEO of Iwabuchi Corporation**

"We believe that <sup>64</sup>Cu, a next-generation medical radionuclide, has the potential to be widely used for both therapeutic and diagnostic purposes in various disease areas. Due to the half-life of radiopharmaceuticals, the establishment of large-scale production capabilities in Japan is essential for the development of new radiopharmaceuticals. We hope that this series of efforts will lead to significant progress toward the commercialization of radiopharmaceuticals using <sup>64</sup>Cu. We also hope to accelerate the development of innovative pharmaceuticals that take advantage of the unique advantages of radiopharmaceuticals, including <sup>64</sup>Cu-ATSM, by combining our group's experience and know-how in radiopharmaceuticals." said **Kiyofumi Kaneshiro, CFO of PeptiDream Inc.**

"We are very honored to join an ambitious project of LinqMed to develop radiopharmaceuticals as "innovative "visible" anti-cancer treatments". Our company has strengths in production of pharmaceuticals and their active ingredients, which can significantly be applicable to this project. Raising our group vision "Change the World", we are practicing our business on the track of "Manufacturing to save the world". Both of LinqMed and our company are commonly headquartered in the Chiba city, therefore, we hope to work together with LinqMed to implement the Chiba-originated radiopharmaceuticals promptly to the medical practice to improve the quality of life of patients in the world." said **Satoshi Shiratori, Representative Director and President of Shiratori Pharmaceutical Co., Ltd.**

#### **About LinqMed Inc.**

LinqMed Inc. is an R&D start-up company developing radiopharmaceuticals to provide innovative "visible" anti-cancer treatments to patients. Our mission is "Link for Life - Linking Innovative Science and Medicine for Your Health and Happiness". LinqMed Inc. has been launched as a certified venture company of the National Institutes for Quantum Sciences and Technology (QST). We are developing radiopharmaceuticals using a copper radioisotope <sup>64</sup>Cu, which can be used for diagnosis and therapy, simultaneously. For more information, please visit our website at <https://www.linqmed.co.jp/>.

**Inquiries:**

**LinqMed Inc.**

Email: [linqmed@linqmed.co.jp](mailto:linqmed@linqmed.co.jp)